source
- Obesity drug market surges as Lilly, Novo Nordisk lead and rivals chase $200B opportunityEli Lilly and Novo Nordisk continue to dominate the early market for obesity treatments, expanding their prescription bases with new oral products. Meanwhile, a range of larger and smaller compani…
- FDA approves Revolution Medicines' Rasonque for metastatic pancreatic cancerRevolution Medicines received FDA approval for its oral RAS inhibitor daraxonrasib, branded as Rasonque, to treat patients with metastatic pancreatic adenocarcinoma who have already received prior…